Dapagliflozin
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Dapagliflozin |
| DrugBank ID | DB06292 |
| Brand Names (EU) | Dapagliflozin Viatris |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.20% |
Approved Indication (EMA)
Type 2 diabetes mellitus Dapagliflozin Viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | classic stiff person syndrome | 98.20% | DL |
| 2 | focal stiff limb syndrome | 98.20% | DL |
| 3 | opsismodysplasia | 98.06% | DL |
| 4 | thiamine-responsive dysfunction syndrome | 98.03% | DL |
| 5 | diabetes mellitus (disease) | 97.88% | DL |
| 6 | drug-induced localized lipodystrophy | 97.03% | DL |
| 7 | centrifugal lipodystrophy | 96.90% | DL |
| 8 | pressure-induced localized lipoatrophy | 96.82% | DL |
| 9 | idiopathic localized lipodystrophy | 96.67% | DL |
| 10 | pancreatic agenesis | 96.59% | DL |
| 11 | autoimmune oophoritis | 90.43% | DL |
| 12 | type 1 diabetes mellitus | 90.33% | DL |
| 13 | diabetes mellitus, insulin-dependent, X-linked, susceptibility to | 63.16% | DL |
| 14 | atrial flutter (disease) | 62.71% | DL |
| 15 | cholangiocarcinoma, susceptibility to | 62.23% | DL |
| 16 | hemoglobin C-beta-thalassemia syndrome | 62.05% | DL |
| 17 | retinal dystrophy with or without extraocular anomalies | 61.78% | DL |
| 18 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 59.39% | DL |
| 19 | congenital temporomandibular joint ankylosis | 59.12% | DL |
| 20 | permanent neonatal diabetes mellitus | 59.03% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.